Walgreens (NASDAQ: WBA) vs CVS (NYSE: CVS): Both Are A Value But There’s Only One I Want To Buy

Friday, July 10, 2020 | Thomas Hughes
Walgreens (NASDAQ: WBA) vs CVS (NYSE: CVS) :Both Are A Value But There’s Only One I Want To BuyA Tale Of Two Drug-Stores

Neither CVS Health Corporation (NYSE: CVS) nor Walgreens Boots Alliance (NASDAQ: WBA) has staged much of a rebound in the post-pandemic world. This is surprising given their status as the largest retailers of staple, consumer-oriented, healthcare products in the post-pandemic world. At today’s prices, both present deep-values for dividend investors but only one stands out as a buy. At least, if you can only buy one, one of them is the clear winner for investment today.

The Dividends: Market-Beating Yield, And Growth Too!

  • CVS is not a Dividend King or even a Dividend Aristocrat but it does have a solid history of past increases. In fact, until just a few years ago, the company had increased its payment for 20 years. The stock is yielding about 3.25% which is closing in on double the broad market average. In terms of safety, the payout ratio is a low 28% of earnings and backed up by a near-fortress balance sheet. Debt is low, cash is ample, and coverage is high. No sign of a suspension or cut in these cards.
  • Walgreens is a Dividend Aristocrat verging on Kingship with 44 years of consecutive annual increases. The 5-year CAGR is a bit lower than that of CVS but offset by a higher expectation of increases and a much better yield. At today’s prices, 13-year lows, this stock is yielding closing to 4.75% with an equally strong balance sheet. The payout ratio is running in the mid-30% range with equally good coverage and debt ratios.

The Earnings Outlook:

  • CVS is expected to post slightly positive revenue and earnings growth in 2020. This will be compounded by an acceleration of growth in 2021 that puts the two-year growth rate (from the pre-COVID through the post-COVID period) at roughly 6% earnings and 6.5% revenue. The analysts are generally bullish on the stock and have been inching their targets and ratings up over the past three months.
  • Walgreens is expected to post steady low-single-digit revenue growth this year and next. The negative in the outlook is that this year’s -12% decline in EPS will not be offset by next year’s 17% rebound. The two-year outlook for growth has consensus for revenue at 4.75% and eps at -7.50%. What is perhaps the mitigating factor is that the two company’s fiscal’s years are not directly comparable. CVS reports 4th quarter earnings in December while Walgreens will do the same next month. In that light, the outlook for Walgreens is robust EPS growth in the range of 12% during the period starting now while CVS’ will be a bit more tepid in the 5% range.
Walgreens (NASDAQ: WBA) vs CVS (NYSE: CVS) :Both Are A Value But There’s Only One I Want To Buy

The Valuations Are Compelling

At face value, both stocks are a deep discount to their average broad-market cousins. Trading in the 7X to 9X forward earnings range these stocks are roughly a third the value of the average S&P stock and at long-term lows compared to their historic averages. The difference is that CVS is trading in the 8-9 range while Walgreens is in the 7-8 range and trading at its long-term lows. CVS is sitting a bit off of its lows suggesting that it will either move down to match WBA or vice versa.

On a technical basis, I prefer Walgreens because it is sitting on potentially very strong support while CVS looks like it may retreat. Add to this the fact of Walgreens’ superior yield, equally strong balance sheet, positive outlook for growth in the current period, and lower valuation and it becomes the winner in my book. If you’re looking for a high-growth rebound play that is lagging the broad market this could be the ticket.

Walgreens (NASDAQ: WBA) vs CVS (NYSE: CVS) :Both Are A Value But There’s Only One I Want To Buy

Featured Article: Hedge Funds - How They Work For Investors


7 Stocks to Buy Now and Avoid a Summer Swoon

Summer is generally a quiet time in the markets. Institutional investors, generally speaking, take some time away. In fact, that’s where the idiom “Sell in May and Go Away” comes from.

But quiet doesn’t mean uneventful. The world still moves along even in the lazy months of summer. And at the moment, there are two conflicting views driving the market.

One is the fear that everything’s a bubble that is just about to burst. We don’t recommend you get out of stocks, but let’s face it, things are more than just a little frothy.

But there’s another view summarized by the acronym, YOLO (as in You Only Live Once). And these investors are committed to keeping the markets going higher. Even if it means going “all in” (whatever that means to them) on risky asset classes like NFTs or Dogecoin.

We sincerely hope you take time to recharge (whatever that means to you) this summer. Whatever your personal beliefs, the reopening of our economy is a moment that deserves to be celebrated by all of us. But before you do, we recommend that you take a peek at these seven stocks that you can consider adding to your portfolio before you check out for the summer. These are likely to get as hot as a firecracker on the Fourth of July and should have you smiling when the summer ends.

View the "7 Stocks to Buy Now and Avoid a Summer Swoon".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
CVS Health (CVS)2.3$85.63+1.2%2.34%15.26Buy$92.82
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.